Specialty drug costs will soar without political will to act

07/12/2013 | Hill, The

The lack of political will to act now will cause the cost of specialty drugs to rise exponentially, writes Dr. Steve Miller, chief medical officer of Express Scripts. Policymakers can address these high costs in the coming months by encouraging the FDA to create a pathway to bring biosimilars, or generic versions of high-cost specialty treatments, into the market faster, he writes. Legislation being pushed by brand-name drugmakers to weaken Medicaid and employers' ability to encourage the use of biosimilars should also be rejected, he writes.

View Full Article in:

Hill, The

Published in Brief: